Concepedia

Thang Ho

TH

Statistics

Publications

3

Citations

571

H-Index

3

Active since

2019

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Thang Ho is an author at Vertex Pharmaceuticals (United States) specializing in pharmacology, immunotherapy, and pediatric therapeutics.

ORCID

Publications per year

2019–2023

3

Publications

3

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 288 citations · Full text

, , +15

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Andréas Mackensen, John B.A.G. Haanen, Christian Koenecke et al. · Nature Medicine · 2023 · 261 citations · Full text

, , +17

Estimating parameters of nonlinear dynamic systems in pharmacology using chaos synchronization and grid search

Nikhil Pillai, Sorell L. Schwartz, Thang Ho et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2019 · 22 citations · Full text

, , +16

1–3 of 3